James D. Thompson

Toxicological and pharmacokinetic properties of QPI-1007, a chemically modified synthetic siRNA targeting caspase 2 mRNA, following intravitreal injection.

D. Kornbrust, Elisabeth C R Solano, Amber Beaudry, 2014, Nucleic acid therapeutics.

Toxicological and pharmacokinetic properties of chemically modified siRNAs targeting p53 RNA following intravenous administration.

B. Molitoris, E. Feinstein, D. Kornbrust, 2012, Nucleic acid therapeutics.

Applications of antisense and siRNAs during preclinical drug development.

James D. Thompson, 2002, Drug discovery today.

Clinical development of synthetic siRNA therapeutics

James D. Thompson, 2013 .

Assessing unintended hybridization-induced biological effects of oligonucleotides

J. Burchard, S. Bartz, M. Lindow, 2012, Nature Biotechnology.

Ribozymes in gene therapy

D. Stinchcomb, D. Macejak, L. Couture, 1995, Nature Network Boston.

siRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injury.

B. Molitoris, E. Feinstein, A. Faerman, 2009, Journal of the American Society of Nephrology : JASN.

Intradermal delivery of modified mRNA encoding VEGF-A in patients with type 2 diabetes

K. Chien, L. Gan, R. Fritsche-Danielson, 2019, Nature Communications.